Wire · opportunities
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The U.S. FDA approved the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) for adult patients with advanced renal cell carcinoma with a clear cell component who have progressed after PD-1/PD-L1 inhibitor therapy, based on positive results from the Phase 3 LITESPARK-011 trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 24 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
Kidney cancer treatment just gained a new regulatory pathway. You in biotech or oncology need to explore partnerships or competitive strategies targeting patients post-PD-1/PD-L1 therapy failing current options.
◆ Coverage
8 sources · first reported 24 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics